Form 4: Eli Lilly Director Acquires Shares Under Deferral Plan
SEC Form 4 Filing
Director J. Erik Fyrwald acquired 12.123 shares of Eli Lilly & Co common stock at $818.02 per share under the Lilly Directors' Deferral Plan.
Summary
- J. Erik Fyrwald, a director of Eli Lilly & Co, acquired 12.123 shares of common stock on April 21, 2025.
- The shares were acquired at a price of $818.02 per share.
- The acquisition was made under the Lilly Directors' Deferral Plan, with shares deferred in lieu of cash compensation as stock units.
- These stock units will be settled in shares of common stock following Fyrwald's separation from service.
- Following the transaction, Fyrwald directly owns 72,839.221 shares of Eli Lilly & Co common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. It reflects a director's continued investment in the company, which is generally viewed favorably, but it's part of a standard compensation plan.
Positives
- The acquisition reflects the director's continued investment in the company.
- The deferral plan allows directors to align their interests with the long-term performance of the company.
Future Outlook
The acquired shares will be settled in shares of common stock following the reporting person's separation from service.
Industry Context
Directors acquiring shares in their own companies is generally seen as a positive sign, indicating confidence in the company's future prospects. Deferral plans are a common way for companies to align the interests of their directors with those of shareholders.
Comparison to Industry Standards
- Director share ownership is a common practice across publicly traded companies.
- Deferral plans are often used to incentivize long-term value creation, similar to practices at companies like Pfizer (PFE) and Merck (MRK).
- The amount of shares acquired is relatively small compared to the total outstanding shares of Eli Lilly, which is typical for director compensation.
Stakeholder Impact
- The transaction signals to shareholders that the director has confidence in the company's future performance.
- The deferral plan aligns the director's interests with those of long-term shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/21/2025 | Date of transaction: J. Erik Fyrwald acquired shares of common stock. |
| 04/22/2025 | Date of signature: Form 4 signed by Jonathan Groff on behalf of J. Erik Fyrwald. |
Keywords
Form 4, Director, Share Acquisition, Lilly Directors' Deferral Plan, Eli Lilly & Co, LLY, Fyrwald, Stock Units, Deferred Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.